Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 98633

Next Previous
Drug Profile

CC 98633

Alternative Names: BCMA NEX T; BCMA-Targeted NEX-T Chimeric antigen receptor (CAR) T Cells - Juno Therapeutics; BMS-986354; CC-98633

Latest Information Update: 06 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 03 Jul 2024 Juno Therapeutics completes a phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT04394650)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (IV, Injection)
  • 10 Dec 2022 Efficacy, pharmacodynamics, pharmacokinetics and adverse events data from phase I trial in Multiple myeloma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top